MacroGenics Inc logo

MGNX - MacroGenics Inc News Story

$19.73 0.2  1.0%

Last Trade - 3:15pm

Mid Cap
Market Cap £868.6m
Enterprise Value £652.4m
Revenue £86.3m
Position in Universe 2833rd / 7277

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

Mon 13th September, 2021 12:00am
For best results when printing this announcement, please click on link below:

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:
MGNX), a biopharmaceutical company focused on developing and commercializing
innovative monoclonal antibody-based therapeutics for the treatment of cancer,
today announced poster presentations relating to multiple investigational
product candidates at the European Society for Medical Oncology (ESMO) Virtual
Conference, taking place September 16-21, 2021.

Posters will be available on September 16, 2021. Details are as follows:

620P - MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with
Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion 
Preliminary clinical results from the Phase 1 cohort expansion study of MGC018
in patients with metastatic castration-resistant prostate cancer and non-small
cell lung cancer will be presented in this poster. The abstract submitted to
ESMO included data as of May 3, 2021, while the final poster will include
updated results as of August 16, 2021.
Presentation Topic: Genitourinary tumours, prostate

1379P - Margetuximab with Retifanlimab in HER2+, PD-L1+ First-Line
Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort
Results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of
margetuximab in combination with retifanlimab in treatment-naïve patients
with locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) who
are positive for both HER2 and PD-L1 will be presented in this poster. The
efficacy data and safety cutoff dates for this poster were July 19, 2021 and
August 3, 2021, respectively.
Presentation Topic: Oesophagogastric cancer

627P - Phase 2 Neoadjuvant Trial of the Anti-B7-H3 Antibody, Enoblituzumab, in
Men with Localized Prostate Cancer: Safety, Efficacy, and Immune Correlates
Results of a Phase 2 neoadjuvant trial of enoblituzumab in men with localized
prostate cancer will be presented in this poster by Johns Hopkins University
School of Medicine.
Presentation Topic: Genitourinary tumours, prostate

926TiP - Phase 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in
First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck
Squamous Cell Carcinoma 
A trial-in-progress poster regarding the Phase 2 study of enoblituzumab, an
Fc‐engineered, anti‐B7‐H3 monoclonal antibody, will be presented.
Presentation Topic: Head and neck cancer, excluding thyroid

The abstracts referenced above were submitted to ESMO in May 2021 and are
available on the ESMO website. The posters will be available for on-demand
viewing on the ESMO website and on the "Events & Presentations" page in the
Investor Relations section of MacroGenics' website at on or around September 16, 2021.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and
commercializing innovative monoclonal antibody-based therapeutics for the
treatment of cancer. The Company generates its pipeline of product candidates
primarily from its proprietary suite of next-generation antibody-based
technology platforms, which have applicability across broad therapeutic
domains. The combination of MacroGenics' technology platforms and protein
engineering expertise has allowed the Company to generate promising product
candidates and enter into several strategic collaborations with global
pharmaceutical and biotechnology companies. For more information, please see
the Company's website at MacroGenics and the MacroGenics
logo are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and
prospects for the Company, including statements about the Company's strategy,
future operations, clinical development of the Company's therapeutic
candidates, commercial prospects of or product revenues from MARGENZA(®),
milestone or opt-in payments from the Company's collaborators, the Company's
anticipated milestones and other statements containing the words "subject to",
"believe", "anticipate", "plan", "expect", "intend", "estimate", "project",
"may", "will", "should", "would", "could", "can", the negatives thereof,
variations thereon and similar expressions, or by discussions of strategy
constitute forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: risks that MARGENZA revenue, expenses and costs may not be as
expected, risks relating to MARGENZA’s market acceptance, competition,
reimbursement and regulatory actions, the uncertainties inherent in the
initiation and enrollment of future clinical trials, expectations of expanding
ongoing clinical trials, availability and timing of data from ongoing clinical
trials, expectations for regulatory approvals, other matters that could affect
the availability or commercial potential of the Company's product candidates
and other risks described in the Company's filings with the Securities and
Exchange Commission. In addition, the forward-looking statements included in
this press release represent the Company's views only as of the date hereof.
The Company anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so, except as may be required by
law. These forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the date hereof
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.